English French Notes Complete/Exclude FIRST COURSE OF TREATMENT - RADIATION 38. REGIONAL DOSE (cGy)...........: 39. BOOST DOSE (cGy)..............: 40. INTRA-OPERATIVE RADIATION 41. CONCURRENT CHEMOTHERAPY.......: FIRST COURSE OF TREATMENT - CHEMOTHERAPY 42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED: 43. INTRAPERITONEAL CHEMOTHERAPY..: 44. CHEMOTHERAPEUTIC TOXICITY.....: 45. CHEMOTHERAPY/SURGERY SEQUENCE.: FIRST COURSE OF TREATMENT - IMMUNOTHERAPY 46. ADMINISTRATION OF INTERFERON..: TREATMENT COMPLICATIONS CASE REGISTRATION 48. INITIALS OF CASE ABSTRACTOR...: 49. DATE CASE WAS ABSTRACTED......: The Accession Year is not 2000. 2000 Patient Care Evaluation Study of Hepatocellular Cancers 1. FACILITY ID NUMBER (FIN) 5. PLACE OF BIRTH 6. DATE OF BIRTH 8. SPANISH ORIGIN 10. PRIMARY PAYER AT DIAGNOSIS 1. FACILITY ID NUMBER (FIN) 5. PLACE OF BIRTH 6. DATE OF BIRTH 8. SPANISH ORIGIN 1. FACILITY ID NUMBER (FIN)......: 2. ACCESSION NUMBER..............: 3. SEQUENCE NUMBER...............: 9 4. POSTAL CODE AT DIAGNOSIS...... 7 5. PLACE OF BIRTH................ 6. DATE OF BIRTH.................: 9 8. SPANISH ORIGIN................ 18 10. PRIMARY PAYER AT DIAGNOSIS.... 11. CLASS OF CASE 13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS 14. ALCOHOL CONSUMPTION 15. TUMOR MARKERS 16. TESTS RELATED TO LIVER FUNCTION 17. RADIOLOGICAL EVALUATION 18. DEFINITIVE DIAGNOSIS 19. DATE OF INITIAL DIAGNOSIS 22. DIAGNOSTIC CONFIRMATION TUMOR IDENTIFICATION 11. CLASS OF CASE.................: 1000 ORAL CONTRACEPTIVES.......... 1001 ESTROGEN REPLACEMENT......... 13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS: 1012 14. ALCOHOL CONSUMPTION........... 15. TUMOR MARKERS: 16. TESTS RELATED TO LIVER FUNCTION: 17. RADIOLOGICAL EVALUATION: CT ARTERIAL PORTOGRAPHY: 1022 VASCULAR INVASION............ 1023 BILOBAR DISEASE.............. 1024 LYMPH NODES.................. 1025 SIZE OF DOMINANT TUMOR (mm).. 1026 NUMBER OF TUMORS............. SPIRAL CT: 1029 VASCULAR INVASION............ 1030 BILOBAR DISEASE.............. 1031 LYMPH NODES.................. 1032 SIZE OF DOMINANT TUMOR (mm).. 1033 NUMBER OF TUMORS............. INCREMENTAL CT: 1036 VASCULAR INVASION............ 1037 BILOBAR DISEASE.............. 1038 LYMPH NODES.................. 1039 SIZE OF DOMINANT TUMOR (mm).. 1040 NUMBER OF TUMORS............. 1043 VASCULAR INVASION............ 1044 BILOBAR DISEASE.............. 1045 LYMPH NODES.................. 1046 SIZE OF DOMINANT TUMOR (mm).. 1047 NUMBER OF TUMORS............. 1050 VASCULAR INVASION............ 1051 BILOBAR DISEASE.............. 1052 LYMPH NODES.................. 1053 SIZE OF DOMINANT TUMOR (mm).. 1054 NUMBER OF TUMORS............. 1055 18. DEFINITIVE DIAGNOSIS.......... 19. DATE OF INITIAL DIAGNOSIS.....: 22. DIAGNOSTIC CONFIRMATON........: VASCULAR INVASION............: NA BILOBAR DISEASE..............: NA LYMPH NODES..................: NA SIZE OF DOMINANT TUMOR (mm)..: Not performed NUMBER OF TUMORS.............: Not performed VASCULAR INVASION............: Unknown BILOBAR DISEASE..............: Unknown LYMPH NODES..................: Unknown 23. SIZE OF TUMOR 24. REGIONAL NODES EXAMINED 25. REGIONAL NODES POSITIVE 26. AJCC CLINICAL STAGE (cTNM) 27. AJCC PATHOLOGIC STAGE (pTNM) 28. STAGED BY STAGE OF DISEASE AT DIAGNOSIS 29 23. SIZE OF TUMOR ................ 33 24. REGIONAL NODES EXAMINED....... 32 25. REGIONAL NODES POSITIVE....... 26. AJCC CLINICAL STAGE (cTNM): 37.1 AJCC CLINICAL T.............. 37.2 AJCC CLINICAL N.............. 37.3 AJCC CLINICAL M.............. 27. AJCC PATHOLOGIC STAGE (pTNM): 85 AJCC PATHOLOGIC T............ 86 AJCC PATHOLOGIC N............ 87 AJCC PATHOLOGIC M............ 28. STAGED BY: 19 CLINICALLY STAGED BY......... 89 PATHOLOGICALLY STAGED BY..... 29. DATE OF FIRST COURSE OF TREATMENT 30. DATE OF INPATIENT ADMISSION 31. DATE OF INPATIENT DISCHARGE 32. DATE OF NON CANCER-DIRECTED SURGERY 33. NON CANCER-DIRECTED SURGERY 34. DATE OF CANCER-DIRECTED SURGERY 35. SURGICAL APPROACH 36. SURGERY OF PRIMARY SITE 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR 39. SURGICAL MARGINS 40. DISTANCE OF TUMOR TO CLOSEST MARGIN 41. SURGERY OF REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S) 42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR 43. RECONSTRUCTION/RESTORATION-FIRST COURSE 44. DATE RADIATION STARTED 45. RADIATION THERAPY 46. DATE CHEMOTHERAPY STARTED 48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED 49. ROUTE CHEMOTHERAPY ADMINISTERED 50. CHEMOTHERAPY/SURGERY SEQUENCE OTHER THERAPY 51. DATE OTHER TREATMENT STARTED 52. OTHER TREATMENT 53. ARTERIAL EMBOLIZATION 54. DEATH WITHIN30 DAYS OF START OF INTIIAL COURSE OF THERAPY FIRST COURSE OF TREATMENT 29. DATE OF FIRST COURSE OF 1 30. DATE OF INPATIENT ADMISSION... 1.1 31. DATE OF INPATIENT DISCHARGE... 32. DATE OF NON CANCER-DIRECTED 33. NON CANCER-DIRECTED SURGERY...: 34. DATE OF CANCER-DIRECTED 35. SURGICAL APPROACH.............: 36. SURGERY OF PRIMARY SITE.......: 37. RADIO-FREQUENCY DESTRUCTION OF 1056 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR........................ 38. ABLATION & RESECTION..........: Ablation & resection not administered 39. SURGICAL MARGINS..............: 40. DISTANCE OF TUMOR TO CLOSEST 1058 40. DISTANCE OF TUMOR TO CLOSEST MARGIN....................... 41. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S).....: 42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR: FIRST COURSE.................: 44. DATE RADIATION STARTED........: 45. RADIATION THERAPY.............: 46. DATE CHEMOTHERAPY STARTED.....: 48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED: CISPLATIN....................: Unknown if recommended or administered FUDR.........................: Unknown if recommended or administered 5-FU.........................: Unknown if recommended or administered FU & LEUCOVORIN..............: Unknown if recommended or administered IRINOTECAN (CPT-11)..........: Unknown if recommended or administered MITOMYCIN C..................: Unknown if recommended or administered OXALIPLATIN..................: Unknown if recommended or administered GEMCITABINE..................: Unknown if recommended or administered 49. ROUTE CHEMOTHERAPY ADMIN......: NA 1069 49. ROUTE CHEMOTHERAPY ADMIN 50. CHEMOTHERAPY/SURGERY SEQUENCE.: No chemotherapy and/or no surgery 50. CHEMOTHERAPY/SURGERY SEQUENCE.: Chemotherapy before surgery 1070 50. CHEMOTHERAPY/SURGERY SEQUENCE. OTHER THERAPY 51. DATE OTHER TREATMENT STARTED..: 52. OTHER TREATMENT...............: 1071 53. ARTERIAL EMBOLIZATION......... 1072 54. DEATH WITHIN 30 DAYS OF START OF INITIAL COURSE OF THERAPY. 55. DATE OF FIRST RECURRENCE 56. TYPE OF FIRST RECURRENCE 55. TYPE OF FIRST RECURRENCE 56. DATE OF FIRST RECURRENCE 70 55. DATE OF FIRST RECURRENCE 71 56. TYPE OF FIRST RECURRENCE 57. DATE OF LAST CONTACT OR DEATH 58. VITAL STATUS 59. CANCER STATUS 57. DATE OF LAST CONTACT OR DEATH..: 15 58. VITAL STATUS................... 59. CANCER STATUS..................: 1. FACILITY ID NUMBER (FIN)....: 2. ACCESSION NUMBER............: 3. SEQUENCE NUMBER.............: 4. POSTAL CODE AT DIAGNOIS.....: 5. PLACE OF BIRTH..............: 6. DATE OF BIRTH...............: 8. SPANISH ORIGIN..............: 10. PRIMARY PAYER AT DIAGNOSIS..: TUMOR IDENTIFICATION 11. CLASS OF CASE...............: ORAL CONTRACEPTIVES........: ESTROGEN REPLACEMENT.......: 14. ALCOHOL CONSUMPTION.........: 15. TUMOR MARKERS: 16. TESTS RELATED TO LIVER FUNCTION: CT ARTERIAL PORTOGRAPHY: VASCULAR INVASTION.........: BILOBAR DISEASE............: LYMPH NODES................: SIZE OF DOMINANT TUMOR (MM): NUMBER OF TUMORS...........: SPIRAL CT: INCREMENTAL CT: 18. DEFINITIVE DIAGNOSIS........: 19. DATE OF INITIAL DIAGNOSIS...: 22. DIAGNOSTIC CONFIRMATION.....: Print Hepatocellular Cancer PCE STAGE OF DISEASE AT DIAGNOSIS 23. SIZE OF TUMOR...............: 24. REGIONAL NODES EXAMINED.....: 25. REGIONAL NODES POSITIVE.....: 26. AJCC CLINICAL STAGE (cTNM): AJCC CLINICAL T............: AJCC CLINICAL N............: AJCC CLINICAL M............: AJCC CLINICAL STAGE GROUP..: 27. AJCC PATHOLOGIC STAGE (pTNM): AJCC PATHOLOGIC T..........: AJCC PATHOLOGIC N..........: AJCC PATHOLOGIC M..........: AJCC PATHOLOGIC STAGE GROUP: 28. STAGED BY: CLINICALLY STAGED BY.......: PATHOLOGICALLY STAGED BY...: FIRST COURSE OF TREATMENT 29. DATE OF FIRST COURSE OF 30. DATE OF INPATIENT ADMISSION.: 31. DATE OF INPATIENT DISCHARGE.: 32. DATE OF NON CANCER-DIRECTED 33. NON CANCER-DIRECTED SURGERY.: 34. DATE OF CANCER-DIRECTED 35. SURGICAL APPROACH...........: 36. SURGERY OF PRIMARY SITE.....: 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR...................: 39. SURGICAL MARGINS............: 40. DISTANCE OF TUMOR TO CLOSEST 41. SURGERY OF OTHER REGIONAL OR DISTANT LYMPH NODE(S)...: FIRST COURSE...............: 44. DATE RADIATION STARTED......: 45. RADIATION THERAPY...........: 46. DATE CHEMOTHERAPY STARTED...: 49. ROUTE CHEMOTHERAPY ADMIN....: 50. CHEMOTHERAPY/SURGERY SEQ....: 51. DATE OTHER TREATMENT STARTED: 52. OTHER TREATMENT.............: 53. ARTERIAL EMBOLIZATION.......: 54. DEATH WITHIN 30 DAYS OF START OF INITIAL COURSE OF 55. DATE OF FIRST RECURRENCE....: 56. TYPE OF FIRST RECURRENCE....: 57. DATE OF LAST CONTACT/DEATH..: 58. VITAL STATUS................: 59. CANCER STATUS...............: The Class of Case code is not 0, 1, 2 or 5. The Behavior Code is not 0, 1 or 3. 2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors 2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors 10. PRIOR EXPOSURE TO RADIATION 11. PRIMARY PAYER AT DIAGNOSIS 12. PRIOR MEDICAL CONDITIONS 14. GENETIC PREDISPOSITION 15. USUAL OCCUPATION 16. USUAL INDUSTRY 5. DATE OF BIRTH.................: 9 7. SPANISH ORIGIN................ 403 10. PRIOR EXPOSURE TO RADIATION... 18 11. PRIMARY PAYER AT DIAGNOSIS.... 12. PRIOR MEDICAL CONDITIONS: 1202 MULTIPLE SCLEROSIS (MS)...... 354 MYOCARDIAL INFARCTION (MI)... 1204 CEREBROVASCULAR DISEASE...... 1208 MALIGNANT MELANOMA........... 1209 OTHER SKIN CANCER............ 1211 COLON OR OTHER GI CANCERS.... 14. GENETIC PREDISPOSITION: 1214 VON HIPPEL-LINDAU DISEASE.... 1215 TUBEROUS SCLEROSIS........... 1216 TURCOT SYNDROME.............. 1217 LI-FRAUMENI SYNDROME......... 1218 KOWDEN DISEASE............... 1219 NEVOID BASAL CELL CARCINOMA.. 15. USUAL OCCUPATION..............: 16. USUAL INDUSTRY................: 17. CLASS OF CASE 19. NEUROLOGICAL FINDINGS 20. PRE-THERAPY DIAGNOSTIC STUDIES 21. TUMOR LOCATION/INVOLVEMENT #################### #################### #################### #################### #################### #################### #################### #################### #################### #################### #################### #################### #################### #################### ####################